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P ROPIRAM fumarate is a new potent
analgesic shown to be highly effec-
tive in various types of pain.1 In post-
operative patients, Forrest et al.2 re-
ported oral propiram to be about one
tenth as potent as intramuscular mor-
phine. Thus, an oral dose of 50 mg pro-
piram is approximately equivalent to




The purpose of this study was to de-
termine the safety and effectiveness (pain
relief and duration) of 50 mg propiram
fumarate in a double-blind comparison
using 50 mg pentazocine hydrochloride,
60 mg codeine sulfate, and placebo as
controls.
Material and Methods
Subjects for this study were selected
from among surgical patients of both
sexes, 18 to 65 years of age, who corn-
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plained of severe pain following a surgi-
cal procedure. The type of surgery varied
from herniorrhaphies and cholecystecto-
mies to hemorrhoidectomies and various
orthopedic procedures. All patients com-
plained of severe pain at the site of the
operation and required a potent analgesic
for symptom relief. A prestudy physical
and laboratory examination (hematology,
urinalysis, blood chemistry) were carried
out to exclude those patients with severe
liver and renal disease. Patients with
known history of physical dependence on
narcotics were excluded.
A washout period of at least 4 hours
was required before empaneling patients
who had previously received other anal-
gesic, sedatives, tranquilizers, psycho-
tropics, or antiinfiammatory medications.
Patients were then randomly assigned on
a double-blind basis to take either of four
preparations: 50 mg propiram fumarate,
50 mg pentazocine hydrochloride, 60 mg
codeine sulfate, and placebo. Randomiza-
tion was in blocks of four. To achieve
double blinding, pentazocine and codeine
tablets were encapsulated, and matching
placebo capsules were prepared. Also pre-
pared were placebo tablets matching pro-
piram fumarate. Patients assigned to the
active medications received a tablet and
a capsule, one of which was an active
drug and the other a placebo. The pla-
cebo group received a placebo tablet and
placebo capsule. Each patient was as-
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signed a treatment unit identified by the
code number. Actual identity of the unit
was sealed in an envelope and kept un-
opened during the clinical trial.
After postoperative drug administra-
tion, patients were interviewed by a
trained nurse observer to evaluate the de-
gree of pain relief and to elicit any ad-
verse effects. Evaluations were done #{189}
hour after drug administration and at
hourly intervals thereafter up to 6 hours.
At each observation period the degree of
pain was evaluated as: 1 = none; 2 =
mild; 3 = moderate; and 4 = severe. A
known analgesic was given if at the end
of 2 hours the patient failed to obtain any
relief. The pain intensity measurement
at the time of remedication was arbitrar-
ily assigned to the rest of the observa-
tion periods, provided the patient was
not remedicated before 2 hours. Patients
vomiting within 30 minutes after drug
intake were disqualified. Patients were
awakened at each evaluation point if
asleep. Side effects were listed only if
directly observed or described by the pa-
tient. All patients were in the study for
only one day, and observations were made
after a single dose of the medication.
The analgesic effectiveness of propiram
fumarate was determined by comparing
the amount of pain reduction (the dif-
ference between the pain intensity at the
specific period and the baseline pain) with
those of the controls. The value obtained
was referred to as the PID (pain inten-
sity difference). Comparison of the mean
PID value at each observation period was
then carried out between the treatment
groups to see if statistically significant
differences existed. In addition, the SPID
(sum of pain intensity difference) was
calculated by summing up the PIP values
of several observation periods and by sta-
tistically comparing the results between
groups. Further, the patients’ need to be
remedicated was compared between treat-
ment groups.
The parameters age, height, weight, and
time of remedication were analyzed via
the Kruskal-Wallis test. If a significant
(P < 0.10) treatment effect was found,
treatments were compared pairwise via
the Mann-Whitney U test. The compari-
son of treatments according to the dis-
tribution of patients by sex, race (Cauca-
sian vs. non-Caucasian), proportion re-
medicated, and presence of side effects
was performed using Fisher’s Exact Test
(2 by 4). Pain scores and SPID were
analyzed at each time point via a two-
factor (treatment, initial pain severity)
analysis of variance. If the treatment’s
main effect was significant (P <0.10)
and the two-factor interaction was non-
significant (P < 0.10), then the overall
treatment means were compared via
Duncan’s multiple range test.
Results
Demographics. There were 55 (28 male,
27 female) patients who successfully
completed the study. They ranged in age
from 20 to 61 years; mean height was
167.6 cm (range 152.4 to 190.0 cm); and
mean weight was 71.6 kg (range 79.4 to
108.8 kg).
Efficacy. Mean pain scores over time
are shown in Fig. 1. Propiram was favored
over placebo at 2 (P <0.05), 3 (P <
0.01), and 4 (P < 0.05) hours, while pen-
tazocine and codeine were favored over
placebo only at 3 hours (P < 0.05) after
drug administration. SPID scores (Table
I) showed all active treatments signifi-
cantly (P < 0.05) superior to placebo.
No significant differences were noted be-
tween the active drugs. Patients require-
ments for remedication (Table II) showed
propiram and pentazocine slightly favored
over codeine but highly favored over pla-
cebo.
Adverse Effects. The most common side
effects encountered were drowsiness, nau-
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Fig. 1. Mean pain scores over time in patients
with severe initial pain: ( ) propiram
50 mg; (---) codeine 60 mg; (._ - -)
pentazocine 50 mg; ( ) placebo (N =
55).
rate group, one out of 16 (6 per cent)
reported nausea, four of 16 (25 per cent)
had drowsiness, and one of 16 (6 per
cent) reported dizziness. In comparison,
among pentazocine-treated patients, three
of 13 (23 per cent) reported nausea, eight
of 13 (61 per cent) reported drowsiness,
and one of 13 (8 per cent) had dizziness.
None of the codeine-treated patients re-
ported nausea, but four of 14 (28 per
cent) reported drowsiness and two of 14
(14 per cent) had dizziness. Interestingly,
the same type of side effects were en-
countered among the placebo-treated pa-
tients: two of 12 (16 per cent) had nau-
sea, four of 12 (33 per cent) had drowsi-
ness, but none was dizzy, although one
patient on placebo developed vertigo.
Discussion
Propiram fumarate was shown to be
effective in the treatment of severe pain
following surgery as measured by sub-
jective evaluation of pain relief. Its anal-
gesic effectiveness was demonstrated to be
statistically significant over placebo and
equivalent to the active controls-60 mg
codeine sulfate and 50 mg pentazocine
hydrochloride. Analgesia was most evident
at the 2nd and 3rd hour after adminis-
tration of propiram fumarate.
The time of remedication confirms these
results. Since the need for remedication
is contingent on a patient’s failure to ob-
tain adequate relief of pain from the ini-
tial treatment, the earlier the patient re-
quires remedication, the less effective is
the initial drug. Thus, on the basis of
this criterion, Table II shows that pro-
piram fumarate and pentazocine hydro-
chloride are both better than placebo and
slightly better than codeine.
As anticipated, drowsiness and nausea
were the most common side effects en-
countered in this study. However, there
were no differences in incidence of side
effects between the three active analgesics
compared. No side effects required treat-
ment.
Summary
The safety and effectiveness of a single
oral dose of 50 mg propiram fumarate as
an analgesic was compared in a double-
blind clinical trial trial against single
doses of standard reference analgesics
(50 mg pentazocine hydrochloride or 60
mg codeine sulfate) or placebo. Subjects













* Actives favored over placebo (P < 0.05) at
4 and 6 hours.
Treatment group
Severe pain ( % patients) *
1 hr 2 hr 3 hr 4 hr 5 hr 6 hr
Propiram 25 37 50 87 87 87
Codeine 35 57 71 100 100 100
Pentazocine 30 38 46 92 92 92
Placebo 41 66 83 100 100 100
* Percentage figures are progressively
period.
postsurgical pain. Mean pain scores and
SPID scores showed all three active
drugs to be favored (P < 0.05) over pla-
cebo in patients with severe initial pain.
The most common side effects seen were
drowsiness, nausea, and dizziness. These
were not severe enough to require treat-
ment. Propiram fumarate (50 mg) was
shown to be an effective and safe anal-
gesic in the treatment of severe postsur-
gical pain.




cummulative at each subsequent time
Acknowledgments
The author would like to thank Sara Re-
pasky, R.N., Darlene Uroda, R.N., and Linda
Yonutas, R.N., for their assistance in this
study.
References
1. Hullmann, H., Sommer, J., and Hoffmeister,
F.: Propiram fumarate in a clinical study.
Arzneimittei-Forsch. 24:718 (1974).
2. Forrest, W. H., Brown, C. B.., Sehrolf, P.,
and Teutseh, G.: Relative potency of pro-
piram and morphine for analgesia in man.
J. Chn. Pharm. 12:440 (1972).
